100 likes | 322 Views
2 nd Annual CDRH/CBER Stakeholder Meeting November 18, 2004 Gaithersburg, MD. Modular PMA Updates. Thinh Nguyen CDRH/ODE. Modular PMA Guidance. Revisions: Panel track supplements, i.e., those with pre-clinical data, may be submitted as modular PMA
E N D
2nd Annual CDRH/CBER Stakeholder MeetingNovember 18, 2004Gaithersburg, MD Modular PMA Updates Thinh Nguyen CDRH/ODE
Modular PMA Guidance • Revisions: • Panel track supplements, i.e., those with pre-clinical data, may be submitted as modular PMA • Modules may be submitted at the same time if acceptable to review division
Modular Data FY 00 – FY 03 • Number of modules are decreasing (per FDA guidance document) • Modules are more complex (e.g., pre-clinical vs. biocompatibility) • Wide variability in the number of review days • Review time is unpredictable
Proposed Performance GoalOption #1 • The following cycle goal will applied: • For FY 06, 70% of the modules received will have an action taken within 120 days for each review cycle • For FY 07, 80% of the modules received will have an action taken within 120 days for each review cycle • Advantage – More predictability • Disadvantage – Longer review time
Proposed Performance GoalOption #2 • The following cycle goal will applied: • For FY 06, 50% of the modules received will have an action taken within 90 days for each review cycle • For FY 07, 60% of the modules received will have an action taken within 90 days for each review cycle • Advantage – Shorter review time • Disadvantage – Less predictability
Modular Performance Goal • Other Options? • Submit to MDUFMA Docket